<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26978565</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis.</ArticleTitle><Pagination><StartPage>e1001975</StartPage><MedlinePgn>e1001975</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1001975</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1001975</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">China accounted for 87% (9.8 million/11.3 million) of all hand, foot, and mouth disease (HFMD) cases reported to WHO during 2010-2014. Enterovirus 71 (EV71) is responsible for most of the severe HFMD cases. Three EV71 vaccines recently demonstrated good efficacy in children aged 6-71 mo. Here we assessed the cost-effectiveness of routine pediatric EV71 vaccination in China.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">We characterized the economic and health burden of EV71-associated HFMD (EV71-HFMD) in China using (i) the national surveillance database, (ii) virological surveillance records from all provinces, and (iii) a caregiver survey on the household costs and health utility loss for 1,787 laboratory-confirmed pediatric cases. Using a static model parameterized with these data, we estimated the effective vaccine cost (EVC, defined as cost/efficacy or simply the cost of a 100% efficacious vaccine) below which routine pediatric vaccination would be considered cost-effective. We performed the base-case analysis from the societal perspective with a willingness-to-pay threshold of one times the gross domestic product per capita (GDPpc) and an annual discount rate of 3%. We performed uncertainty analysis by (i) accounting for the uncertainty in the risk of EV71-HFMD due to missing laboratory data in the national database, (ii) excluding productivity loss of parents and caregivers, (iii) increasing the willingness-to-pay threshold to three times GDPpc, (iv) increasing the discount rate to 6%, and (v) accounting for the proportion of EV71-HFMD cases not registered by national surveillance. In each of these scenarios, we performed probabilistic sensitivity analysis to account for parametric uncertainty in our estimates of the risk of EV71-HFMD and the expected costs and health utility loss due to EV71-HFMD. Routine pediatric EV71 vaccination would be cost-saving if the all-inclusive EVC is below US$10.6 (95% CI US$9.7-US$11.5) and would remain cost-effective if EVC is below US$17.9 (95% CI US$16.9-US$18.8) in the base case, but these ceilings could be up to 66% higher if all the test-negative cases with missing laboratory data are EV71-HFMD. The EVC ceiling is (i) 10%-14% lower if productivity loss of parents/caregivers is excluded, (ii) 58%-84% higher if the willingness-to-pay threshold is increased to three times GDPpc, (iii) 14%-19% lower if the discount rate is increased to 6%, and (iv) 36% (95% CI 23%-50%) higher if the proportion of EV71-HFMD registered by national surveillance is the same as that observed in the three EV71 vaccine phase III trials. The validity of our results relies on the following assumptions: (i) self-reported hospital charges are a good proxy for the opportunity cost of care, (ii) the cost and health utility loss estimates based on laboratory-confirmed EV71-HFMD cases are representative of all EV71-HFMD cases, and (iii) the long-term average risk of EV71-HFMD in the future is similar to that registered by national surveillance during 2010-2013.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared to no vaccination, routine pediatric EV71 vaccination would be very cost-effective in China if the cost of immunization (including all logistical, procurement, and administration costs needed to confer 5 y of vaccine protection) is below US$12.0-US$18.3, depending on the choice of vaccine among the three candidates. Given that the annual number of births in China has been around 16 million in recent years, the annual costs for routine pediatric EV71 vaccination at this cost range should not exceed US$192-US$293 million. Our results can be used to determine the optimal vaccine when the prices of the three vaccines are known.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Joseph T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jit</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Modelling and Economics Unit, Public Health England, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, London School of Hygiene &amp;Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yaming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, Key Laboratory of Surveillance and Early Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Kathy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Weijia</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, Key Laboratory of Surveillance and Early Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, Key Laboratory of Surveillance and Early Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Qiaohong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, Key Laboratory of Surveillance and Early Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowling</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Bingyi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Eric H Y</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Saki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Ecology and Evolutionary Biology, Princeton University, Princeton, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrar</LastName><ForeName>Jeremy J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenfell</LastName><ForeName>Bryan T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Ecology and Evolutionary Biology, Princeton University, Princeton, New Jersey, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Gabriel M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hongjie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, Key Laboratory of Surveillance and Early Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P2C HD047879</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM088558</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>PLoS Med. 2016 Apr 06;13(4):e1002013. doi: 10.1371/journal.pmed.1002013</RefSource><PMID Version="1">27050103</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004526" MajorTopicYN="N">Efficiency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="N">Parents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>BJC has received research funding from MedImmune Inc. and Sanofi Pasteur for studies of influenza vaccine effectiveness, and BJC has consulted for Crucell NV on influenza prevention. None of these companies manufacture EV71 vaccines. All other authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26978565</ArticleId><ArticleId IdType="pmc">PMC4792415</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1001975</ArticleId><ArticleId IdType="pii">PMEDICINE-D-15-01110</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chua KB, Kasri AR. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin. 2011;26:221&#x2013;8. 10.1007/s12250-011-3195-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-011-3195-8</ArticleId><ArticleId IdType="pmc">PMC8222466</ArticleId><ArticleId IdType="pubmed">21847753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341:929&#x2013;935. 10.1056/NEJM199909233411301</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoya M, Kawasaki Y, Sato M, Honzumi K, Kato A, Hiroshima T, et al. Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. Pediatr Infect Dis J. 2006;25:691&#x2013;694. 10.1097/01.inf.0000227959.89339.c3</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000227959.89339.c3</ArticleId><ArticleId IdType="pubmed">16874167</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen NT, Pham HV, Hoang CQ, Nguyen TM, Nguyen LT, Phan HC, et al. Epidemiological and clinical characteristics of children who died from hand, foot and mouth disease in Vietnam, 2011. BMC Infect Dis. 2014;14:341 10.1186/1471-2334-14-341</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-341</ArticleId><ArticleId IdType="pmc">PMC4068316</ArticleId><ArticleId IdType="pubmed">24942066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;14:e1076&#x2013;e1081. 10.1016/j.ijid.2010.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al. Hand, foot, and mouth disease in China, 2008&#x2013;12: an epidemiological study. Lancet Infect Dis. 2014;14:308&#x2013;318. 10.1016/S1473-3099(13)70342-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Western Pacific Region. Emerging disease surveillance and response&#x2014;hand, foot and mouth disease (HFMD). [cited 29 Jan 2015]. http://www.wpro.who.int/emerging_diseases/HFMD/en/.</Citation></Reference><Reference><Citation>Chinese Center for Disease Control and Prevention. National Population and Health Science Data Sharing Platform. [cited 29 Jan 2015]. http://www.phsciencedata.cn/Share/en/index.jsp.</Citation></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097&#x2013;1105. 10.1016/S1474-4422(10)70209-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778&#x2013;790. 10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Western Pacific Region. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). Geneva: World Health Organization; 2011.</Citation></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829&#x2013;837. 10.1056/NEJMoa1303224</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818&#x2013;828. 10.1056/NEJMoa1304923</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;2032. 10.1016/S0140-6736(13)61049-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Yang W, Varma JK. To save children&#x2019;s lives, China should adopt an initiative to speed introduction of pneumonia vaccines. Health Aff (Millwood). 2012;31:2545&#x2013;2553. 10.1377/hlthaff.2011.1272</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2011.1272</ArticleId><ArticleId IdType="pubmed">23129686</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, Liao Q, Van Boeckel TP, Xing W, Sun J, Hsiao VY, et al. Hand, foot, and mouth disease in China: modelling epidemic dynamics of enterovirus serotypes and implications for vaccination. PLoS Med. 2016. 10.1371/journal.pmed.1001958</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001958</ArticleId><ArticleId IdType="pmc">PMC4755668</ArticleId><ArticleId IdType="pubmed">26882540</ArticleId></ArticleIdList></Reference><Reference><Citation>The World Bank. Life expectancy at birth. [cited 29 Jan 2015]. http://data.worldbank.org/indicator/SP.DYN.LE00.IN.</Citation></Reference><Reference><Citation>Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14:171&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">10154656</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pubmed">8849754</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.</Citation></Reference><Reference><Citation>National Bureau of Statistics of China. National data: national accounts. [cited 29 Jan 2015]. http://data.stats.gov.cn/english/easyquery.htm?cn=C01.</Citation></Reference><Reference><Citation>Zhu FC, Liang ZL, Meng FY, Zeng Y, Mao QY, Chu K, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PLoS ONE. 2012;7:e37206 10.1371/journal.pone.0037206</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037206</ArticleId><ArticleId IdType="pmc">PMC3360679</ArticleId><ArticleId IdType="pubmed">22662137</ArticleId></ArticleIdList></Reference><Reference><Citation>Panozzo CA, Becker-Dreps S, Pate V, Weber DJ, Jonsson Funk M, Sturmer T, et al. Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007&#x2013;2010. Am J Epidemiol. 2014;179:895&#x2013;909. 10.1093/aje/kwu001</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwu001</ArticleId><ArticleId IdType="pmc">PMC3969536</ArticleId><ArticleId IdType="pubmed">24578359</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. The guidelines manual: assessing cost effectiveness. 2012 Nov [cited 23 Mar 2015]. https://www.nice.org.uk/article/pmg6/chapter/7-assessing-cost-effectiveness.</Citation></Reference><Reference><Citation>Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. York: University of York Center for Health Economics; 2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5193154</ArticleId><ArticleId IdType="pubmed">27987642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Dong Y, Xu Y. Cost-effectiveness analysis of 4 therapeutic schemes for children herpangina. China Pharmaceuticals. 2011;20:48&#x2013;50.</Citation></Reference><Reference><Citation>Tang X, Li W, Wang W. Cost-minimization analysis of three therapeutic schemes for hand-foot-mouth disease. China Mod Med. 2010;33:095.</Citation></Reference><Reference><Citation>Yang T. Cost-effectiveness analysis of medication treatment for HFMD in children. Chin J Mod Drug Appl. 2012;6:79&#x2013;80.</Citation></Reference><Reference><Citation>He T-F, Yang T-C, Yi B, Xu G-Z. Economic burden estimation for pandemic hand foot and mouth disease in Ningbo City, 2011. Shanghai J Prev Med. 2012;9:001.</Citation></Reference><Reference><Citation>Yang T-C, Yi B, He T-F, Wu Y, Ma Y, Xu G. Economic burden of hand, foot and mouth disease in Ningbo, Zhejiang. Dis Surveill. 2012;27:520&#x2013;523.</Citation></Reference><Reference><Citation>Qin Y, Zhang J, Zhang J, Mou G, Xing Y, Liu J. Investigation on economical burden and status of health care seeking among 1398 hand-foot-mouth disease cases in Yantai. Chin J Epidemiol. 2009;30:1319&#x2013;1320.</Citation></Reference><Reference><Citation>Gan Z-K, Jin H, Li J-X, Yao X-J, Zhou Y, Zhang X-F, et al. Disease burden of enterovirus 71 in rural central China: a community-based survey. Hum Vaccin Immunother. 2015;11:2400&#x2013;2405. 10.1080/21645515.2015.1059980</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1059980</ArticleId><ArticleId IdType="pmc">PMC4635911</ArticleId><ArticleId IdType="pubmed">26158689</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Li H, Li G-F, Hu Y-H. Survey on economic burden of hand, foot and mouth disease in Huaiyin District of Jinan City 2012. Prev Med Trib. 2014;7:484&#x2013;487.</Citation></Reference><Reference><Citation>Liu T. Research on economic burden of disease and its determinants of hand, foot and mouth disease patients in Shandong Province. Jinan: Shandong University; 2013.</Citation></Reference><Reference><Citation>Martin A, Cottrell S, Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ. 2008;11:471&#x2013;484. 10.3111/13696990802321047</Citation><ArticleIdList><ArticleId IdType="doi">10.3111/13696990802321047</ArticleId><ArticleId IdType="pubmed">19450099</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BY, Wateska AR, Bailey RR, Tai JH, Bacon KM, Smith KJ. Forecasting the economic value of an enterovirus 71 (EV71) vaccine. Vaccine. 2010;28:7731&#x2013;7736. 10.1016/j.vaccine.2010.09.065</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.09.065</ArticleId><ArticleId IdType="pmc">PMC2989421</ArticleId><ArticleId IdType="pubmed">20923711</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760&#x2013;768. 10.1016/S1473-3099(11)70090-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(11)70090-1</ArticleId><ArticleId IdType="pubmed">21621466</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14:958&#x2013;966. 10.1016/S1473-3099(14)70841-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(14)70841-2</ArticleId><ArticleId IdType="pubmed">25107680</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>